VistaGen Therapeutics registers $13.8 million common stock offering

Deal also includes up to $1.04 million common stock purchase warrants

By Susanna Moon

Chicago, March 14 – VistaGen Therapeutics, Inc. registered to sell $13.8 million of common stock in an S-1 filing with the Securities and Exchange Commission. The company also registered up to $1,035,000 of common stock purchase warrants.

The company’s stock (OTCBB: VSTA) last closed at $8.00 per share on March 11.

Chardan Capital Markets, LLC and WallachBeth Capital, LLC are the underwriters.

Proceeds will be used for clinical development of AV-101, including funding the expected phase 2b study of AV-101 and also for research and nonclinical development related to the company’s stem cell technology platform, for capital expenditures and for general corporate purposes.

The company is a South San Francisco, Calif.-based biotechnology company focused on stem cells.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.